| Pharmaceutical Information |
| Drug Name |
Guanfacine hydrochloride |
| Drug ID |
BADD_D01047 |
| Description |
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD.[L11277] Guanfacine was first described in the literature in 1974.[A189841]
Guanfacine was granted FDA approval on 27 October 1986.[L11274] |
| Indications and Usage |
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.[L11277] |
| Marketing Status |
approved; investigational |
| ATC Code |
C02AC02 |
| DrugBank ID |
DB01018
|
| KEGG ID |
D00606
|
| MeSH ID |
D016316
|
| PubChem ID |
71401
|
| TTD Drug ID |
D0WD8M
|
| NDC Product Code |
46016-2911; 63552-021; 65372-1177; 70518-3516; 46016-2912; 53747-096; 53069-0080; 63190-0250; 53296-0024; 63552-023; 63552-022; 60687-710; 42291-310; 63552-024; 68071-2719; 29300-458; 29300-459 |
| UNII |
PML56A160O
|
| Synonyms |
Guanfacine | Tenex | Guanfacine Hydrochloride | Hydrochloride, Guanfacine | Guanfacine Monohydrochloride | Monohydrochloride, Guanfacine | Lon798 | BS-100-141 | BS 100 141 | BS100141 | Estulic |
|
| Chemical Information |
| Molecular Formula |
C9H10Cl3N3O |
| CAS Registry Number |
29110-48-3 |
| SMILES |
C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
